C

Corvus Pharmaceuticals
D

CRVS

4.19000
USD
-0.22
(-4.99%)
مغلق
حجم التداول
31,321
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
269,237,882
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    -0.01500
    (-0.44%)
    3.42500 USD
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    R
    RGNX
    -0.08500
    (-1.15%)
    7.28000 USD
    S
    SRPT
    -2.010
    (-1.86%)
    106.280 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).